BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27142338)

  • 21. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Boffetta P; Freedland SJ
    Cancer; 2014 Jan; 120(2):197-204. PubMed ID: 24127391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.
    Haldrup C; Mundbjerg K; Vestergaard EM; Lamy P; Wild P; Schulz WA; Arsov C; Visakorpi T; Borre M; Høyer S; Orntoft TF; Sørensen KD
    J Clin Oncol; 2013 Sep; 31(26):3250-8. PubMed ID: 23918943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia.
    Paradowska A; Fenic I; Konrad L; Sturm K; Wagenlehner F; Weidner W; Steger K
    Int J Oncol; 2009 Jul; 35(1):87-96. PubMed ID: 19513555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenomic alterations in localized and advanced prostate cancer.
    Lin PC; Giannopoulou EG; Park K; Mosquera JM; Sboner A; Tewari AK; Garraway LA; Beltran H; Rubin MA; Elemento O
    Neoplasia; 2013 Apr; 15(4):373-83. PubMed ID: 23555183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cigarette smoking and prostate cancer recurrence after prostatectomy.
    Joshu CE; Mondul AM; Meinhold CL; Humphreys EB; Han M; Walsh PC; Platz EA
    J Natl Cancer Inst; 2011 May; 103(10):835-8. PubMed ID: 21498781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of new differentially methylated genes that have potential functional consequences in prostate cancer.
    Kim JW; Kim ST; Turner AR; Young T; Smith S; Liu W; Lindberg J; Egevad L; Gronberg H; Isaacs WB; Xu J
    PLoS One; 2012; 7(10):e48455. PubMed ID: 23119026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative and integrative analysis of transcriptomic and epigenomic-wide DNA methylation changes in African American prostate cancer.
    Creighton CJ; Zhang F; Zhang Y; Castro P; Hu R; Islam M; Ghosh S; Ittmann M; Kwabi-Addo B
    Epigenetics; 2023 Dec; 18(1):2180585. PubMed ID: 37279148
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Barry KH; Mohanty K; Erickson PA; Wang D; Shi J; Rose G; Cellini A; Clark K; Ambulos N; Yin J; Yan L; Poulin M; Meyer A; Zhang Y; Bentzen SM; Burke A; Hussain A; Berndt SI
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene methylation in gastric cancer.
    Qu Y; Dang S; Hou P
    Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differentially methylated regions in T cells identify kidney transplant patients at risk for de novo skin cancer.
    Peters FS; Peeters AMA; Mandaviya PR; van Meurs JBJ; Hofland LJ; van de Wetering J; Betjes MGH; Baan CC; Boer K
    Clin Epigenetics; 2018; 10():81. PubMed ID: 29946375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer--novel predictor of biochemical recurrence after radical surgery.
    Mitsui Y; Shiina H; Hiraki M; Arichi N; Hiraoka T; Sumura M; Honda S; Yasumoto H; Igawa M
    Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):487-96. PubMed ID: 22246902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality.
    Pidsley R; Lam D; Qu W; Peters TJ; Luu PL; Korbie D; Stirzaker C; Daly RJ; Stricker P; Kench JG; Horvath LG; Clark SJ
    Clin Transl Med; 2022 Oct; 12(10):e1030. PubMed ID: 36178085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor microenvironment deconvolution identifies cell-type-independent aberrant DNA methylation and gene expression in prostate cancer.
    Reynolds SR; Zhang Z; Salas LA; Christensen BC
    Clin Epigenetics; 2024 Jan; 16(1):5. PubMed ID: 38173042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
    Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
    J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer.
    Jiang Q; Xie M; He M; Yan F; Chen M; Xu S; Zhang X; Shen P
    Medicine (Baltimore); 2019 Jan; 98(1):e13820. PubMed ID: 30608394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
    Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
    Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.